drugset / Trial / NCT00680628
Clot Dissolving Treatment for Blood Clots in the Lungs
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine if tenecteplase plus enoxaparin is safe and effective in the treatment of patients with severe submassive pulmonary embolism.
Timeline
- Start
- 2008-05
- Primary completion
- 2012-05
- Completion
- 2012-10
Publications
- Zuo Z, Yue J, Dong BR, Wu T, Liu GJ, Hao Q. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev. 2021 Apr 15;4(4):CD004437. doi: 10.1002/14651858.CD004437.pub6.
- Stewart LK, Peitz GW, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, Diercks DB, Klinger JR, Kline JA. Contribution of fibrinolysis to the physical component summary of the SF-36 after acute submassive pulmonary embolism. J Thromb Thrombolysis. 2015 Aug;40(2):161-6. doi: 10.1007/s11239-014-1155-5.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenecteplase | Protein / enzyme biologic | 30 mg | Intravenous |
| Subject | Tenecteplase | Protein / enzyme biologic | 35 mg | Intravenous |
| Subject | Tenecteplase | Protein / enzyme biologic | 40 mg | Intravenous |
| Subject | Tenecteplase | Protein / enzyme biologic | 45 mg | Intravenous |
| Subject | Tenecteplase | Protein / enzyme biologic | 50 mg | Intravenous |
| Comparator | Enoxaparin sodium | Other / unclassified | 1 mg/kg | Subcutaneous |